Evaluation of histological, serological and clinical changes in response to abatacept treatment of primary Sjögren's syndrome: A pilot study

Adler, Sabine; Körner, Meike; Förger, Frauke; Huscher, Dörte; Caversaccio, Marco-Domenico; Villiger, Peter M. (2013). Evaluation of histological, serological and clinical changes in response to abatacept treatment of primary Sjögren's syndrome: A pilot study. Arthritis care & research, 65(11), pp. 1862-1868. Wiley-Blackwell 10.1002/acr.22052

[img] Text
acr22052.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (235kB) | Request a copy

Objectives To prospectively evaluate histopathologic, blood cellular, serological and clinical changes in response to abatacept treatment in patients with primary Sjögren's syndrome (pSS). Methods Blood, saliva and minor salivary gland biopsies were obtained before and after the last of 8 doses of abatacept in 11 pSS patients. The histologic data evaluated the number of lymphocytic foci and of B- and T-cell subtypes (CD20(+) , CD3(+) , CD4(+) , CD8(+) ). The numbers of FoxP3(+) regulatory T-cells were measured and the FoxP3 /CD 3 ratio was calculated. Histologic data were compared with results from peripheral blood and with changes in saliva secretion. Results The numbers of lymphocytic foci decreased significantly (p=0.041). Numbers of local FoxP3(+) T-cells decreased significantly in percentage of total lymphocytic infiltrates (p=0.037). In the peripheral blood B-cells increased (p=0.038). This was due to an expansion of the naïve B cell pool (p=0.034). When adjusting for disease duration, an increase was also noted for total lymphocytes (p=0.044) and for CD 4 cells (p=0.009). Gamma globulins decreased significantly (p=0.005), but IgG reduction did not reach significance. Adjusted for disease duration, saliva production increased significantly (p=0.029). Conclusions CTLA4-Ig treatment significantly reduces glandular inflammation in pSS, induces several celluar changes and increases saliva production. Remarkably, this increase in saliva production is significantly influenced by disease duration.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Rheumatology, Clinical Immunology and Allergology
04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Ear, Nose and Throat Disorders (ENT)
04 Faculty of Medicine > Service Sector > Institute of Pathology

UniBE Contributor:

Adler, Sabine; Körner Jachertz, Meike; Förger, Frauke; Caversaccio, Marco and Villiger, Peter

Subjects:

600 Technology > 610 Medicine & health
500 Science > 570 Life sciences; biology

ISSN:

0893-7524

Publisher:

Wiley-Blackwell

Language:

English

Submitter:

Stefan Kuchen

Date Deposited:

07 Mar 2014 09:50

Last Modified:

06 Nov 2015 09:19

Publisher DOI:

10.1002/acr.22052

PubMed ID:

23740889

BORIS DOI:

10.7892/boris.42755

URI:

https://boris.unibe.ch/id/eprint/42755

Actions (login required)

Edit item Edit item
Provide Feedback